Abstract FR596: Resistant Hypertension in Pregnancy: Management in a Case of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.fr596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Meghan Taylor und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Case Presentation: A 32-year-old gravida 1 conceived via IVF presented at 12 weeks gestation with hypertensive urgency (BP 181/110) and no hypertensive history. Medical history includes a pathogenic CHEK2 variant associated hereditary leiomyomatosis and renal cancer syndrome (HLRCC), numerous uterine and cutaneous leiomyomas, and 2 prior extensive abdominal myomectomies (Figure 1). She required multiple admissions for severe hypertension, medication titration and work-up (Figure 2). Laboratory evaluation remained normal, except for elevated serum aldosterone (Table). Intermittent urine protein elevations were noted during the pregnancy. Fetus was appropriately grown. She underwent a cesarean delivery at 33 3/7 weeks for refractory hypertension despite treatment with 3 maximally-dosed antihypertensive medications: nifedipine XL, labetalol, and clonidine patch with as needed oral clonidine. Differential Diagnosis: Differential diagnosis included secondary hypertension and hypertensive disorders of pregnancy (HDP). She was diagnosed with resistant essential hypertension based on a negative secondary hypertension work-up, early-onset hypertension, and no evidence of HDP. Treatment and Management: Progressive escalation of 3 antihypertensive medications was needed as pregnancy progressed. Despite this, blood pressure control remained inadequate, necessitating delivery at 33 weeks. Outcome: After delivery, her antihypertensive regimen was deescalated and enalapril was initiated at 2 weeks postpartum. She was transitioned to enalapril monotherapy by 6 weeks. Aldosterone normalized at 6 weeks postpartum. Discussion: The etiology of resistant hypertension in pregnancy can be difficult to determine. In this case, the HLRCC likely played a role. HLRCC is associated with a substantial uterine fibroid burden, high rates of recurrence following myomectomy, and the potential for rapid fibroid proliferation. Risk is further increased during pregnancy. Fibroids are an independent risk factor for the development of hypertensive disorders of pregnancy secondary to angiogenic imbalance and vascular remodeling, endothelial dysfunction and renin-angiotensin-aldosterone system (RAAS) activation. Fibroids express angiotensin II receptors (AT1 and AT2) which respond to angiotensin II and aldosterone by promoting further proliferation and receptor upregulation. Pregnancy is a state of hyperreninemic hyperaldosteronism. In this patient, the numerous enlarging fibroids along with the normal physiologic changes of pregnancy may have potentiated the hyperaldosteronism, contributing to the profound treatment-resistant hypertension. Prompt blood pressure normalization postpartum following initiation of RAAS inhibition further supports this mechanism.
Zitieren
APA
Taylor, M., Bhasin, M., Kattah, A., & Szymanski, L. (2026). Abstract FR596: Resistant Hypertension in Pregnancy: Management in a Case of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.fr596
Vancouver
Taylor M, Bhasin M, Kattah A, Szymanski L. Abstract FR596: Resistant Hypertension in Pregnancy: Management in a Case of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.fr596
BibTeX
@article{Taylor2026,
author = {Taylor, Meghan and Bhasin, Medhavi and Kattah, Andrea and Szymanski, Linda},
title = {Abstract FR596: Resistant Hypertension in Pregnancy: Management in a Case of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.fr596}
}
EUVIMED